<DOC>
	<DOC>NCT03025958</DOC>
	<brief_summary>Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma</brief_summary>
	<brief_title>Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Elderly patients with locoregionally advanced nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent radiotherapy, weekly nimotuzumab (200 mg/week).</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Previously untreated and histologically confirmed locoregionally advanced nasopharyngeal carcinoma A history of another invasive cancer, prior RT to the head and neck area, prior cytotoxic chemotherapy or antiEGFR therapy or the presence of any serious medical conditions, supposed to live less than 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>